MarginsXMarginsX
Home › Markets › Health Care › VNRX

VolitionRX Limited (VNRX)

VNRX trades on NYSE in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1998
-13.13% on the day
Market cap
$7.2M
Nano cap
Revenue · 2025
$1.7M
+40.0% on 2024
Net income · 2025
-$23.4M
-1352.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/93314/000147793226001832/0001477932-26-001832-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVNRX on NYSE
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountrySingapore
IPO year2015
SEC CIK0000093314
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.7M
Net income-$23.4M
Operating income-$21.7M
Net margin-1352.2%
Operating margin-1258.5%
Revenue growth+40.0%
Cash$1.1M
Total assets$6.9M
P/E (computed)Net income was not positive
P/S (computed)4.2×

Warning signs

Cash runway
1.4 months
$2.4M cash at September 30, 2026
Share count, 1 year
+487.7%
2025-11-07 to 2026-11-05 · +817.1% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$137K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"For these reasons, management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing."
10-Q 2026-11-12
Cash and burn$2.4M cash; operating cash flow -$5.1M a quarter.Report 2026-09-30
Shares outstanding36,082,903 (2026-11-05); 122,801,572 a year earlier; 78,685,873 three years earlier. 1y figure adjusted for split (1-for-20 overall); 3y figure adjusted for split (1-for-20 overall).Cover page 2026-11-05
Reverse splits, 3 years1; latest 1-for-20 on 2026-04-28Source 2026-04-28
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-09
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-04-23
AuditorSadler, Gibb & Associates, LLC, Draper, Utah, United StatesPCAOB Form AP 2026-04-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $137K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.6M-$3.8M-$4.6M$2.4M$6.7M$3.4M10-Q 2026-11-12
Q2 2026
2026-06-30
$399K-$7.3M-$5.2M$2.8M$7.1M$2.5M10-Q 2026-08-13
Q1 2026
2026-03-31
$985K-$6.7M-$5.3M$3.1M$7.3M$2.5M10-Q 2026-05-14
Q4 2025
2025-12-31
$447K-$6.3M-$5.5M$1.1M$6.7M$1.7M10-K 2026-03-31
Q3 2025
2025-09-30
$627K-$5.4M-$3.6M$200K$6.5M$1.5M10-Q 2026-11-12
Q2 2025
2025-06-30
$407K-$6.3M-$6.3M$2.3M$6.8M$1.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$246K-$5.4M-$4.3M$2.6M$6.4M$1.3M10-Q 2026-05-14
Q4 2024
2024-12-31
$192K-$5.8M-$5.4M$3.3M$4.8M$1.2M10-K 2026-03-31

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32026-08-28
Latest annual report
FORM 10-K/A
10-K/A2026-04-30
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxyDEF 14A2026-06-02

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+15.0%
1 month+27.8%
3 months-63.5%
Year to date-95.6%
1 year-96.7%
From 52-week high-96.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
BMRABiomerica Inc.$1.32-2.94%$6.1M
CDIOCardio Diagnostics Holdings Inc.$1.79-7.26%$5.3M
TRIBTrinity Biotech plc$5.38-11.89%$4.4M
QCLSQ/C Technologies Inc.$0.3210+4.80%$2.6M
IMDXInsight Molecular Diagnostics Inc.$1.86-13.08%$60.9M
VRAXVirax Biolabs Group Limited$0.4480-26.87%$603K
ICCCImmuCell Corporation$11.42+6.23%$103.8M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier